Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Wu
    Wu
  10. Wolden
    Wolden

Groups

  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)
  7. Center for Hematologic Malignancies (1674)
  8. Hematologic Malignancies, Division of (1609)
  9. Gynecology Disease Management Team (1425)
  10. Sloan Kettering Institute Faculty (1413)
Search Within
Formats
  1. Journal Article (7387)
  2. Meeting Abstract (4694)
  3. Review (616)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Meeting Abstract

    Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • SVR (spleen volume reduction) predicts OS (overall survival) in MF (myelofibrosis) patients on PAC (pacritinib) but not BAT (best available therapy): PERSIST-2 landmark OS analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • The randomized Phase III SIERRA (Study of Iomab-B in Elderly relapsed or refractory AML) trial: Successful allogeneic hematopoietic stem cell transplantation using treatment with Iomab-B-led regimen for patients with active, relapsed or refractory AML with failed targeted therapies
    Meeting Abstract

    Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Abboud, C.; Koshy, N.; Stiff, P. J.; Tomlinson, B.; Abhyankar, S.; Foran, J. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial
    Meeting Abstract

    Apperley, J.; Cortes, J.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M.; Lipton, J. H.; Lomaia, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Post hoc analysis of patient responses by T315I mutation status from the 3-year update of the optic trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Real-world (RW) outcomes with venetoclax (VEN) in patients with acute myeloid leukemia (AML) from COTA, a US RW evidence database
    Meeting Abstract

    Stein, E.; Hodzic, S.; Owusu, H.; Pathak, D.; Zhou, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Racial and ethnic disparities in outcomes following hematopoietic stem cell transplant (HCT) in patients with severe combined immunodeficiency (SCID)
    Meeting Abstract

    Winestone, L.; Logan, B. R.; Liu, X.; Buckley, R. H.; O'Reilly, R. J.; Griffith, L. M.; Puck, J.; Dvorak, C. C.; Cowan, M. J.; Haddad, E.
    Clinical Immunology (2023)

    Fulltext@MSK | Save
  • Sequencing patterns and treatment effectiveness in ALK-positive aNSCLC following first-line alectinib or brigatinib
    Meeting Abstract

    Preeshagul, I.; Abrahami, D.; Li, B.; Thomaidou, D.; Duncan, K.; Krulewicz, S.; Rupp, M.; Bauman, J.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Tepotinib and capmatinib in patients with MET exon 14 skipping NSCLC: A matching adjusted indirect comparison (MAIC)
    Meeting Abstract

    Pfeiffer, B. M.; Postma, M. J.; Hatswell, A.; Vioix, H.; Paik, P. K.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • High-risk clinicopathologic and genomic features of recurrence in stage I lung adenocarcinoma
    Meeting Abstract

    Fick, C. N.; Dunne, E. G.; Mastrogiacomo, B.; Tan, K. S.; Toumbacaris, N.; Adusumilli, P. S.; Rocco, G.; Molena, D.; Huang, J.; Park, B. J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save